Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: Results of an international study

Blood

Volumn 117, Issue 26, 2011, Pages 7102-7111

  Coenen, Eva A ^a   Raimondi, Susana C ^b,c   Harbott, Jochen ^d   Zimmermann, Martin ^e   Alonzo, Todd A ^c   Auvrignon, Anne ^f   Beverloo, H Berna ^g,h   Chang, Myron ^c   Creutzig, Ursula ⁱ   Dworzak, Michael N ^j   Forestier, Erik ^k   Gibson, Brenda ^l   Hasle, Henrik ^m   Harrison, Christine J ⁿ   Heerema, Nyla A ^c,o   Kaspers, Gertjan J L ^p,q,r   Leszl, Anna ^s   Litvinko, Nathalia ^t   Lo Nigro, Luca ^u   Morimoto, Akira ^v,w   Perot, Christine ^f   Reinhardt, Dirk ^e   Rubnitz, Jeffrey E ^b   Smith, Franklin O ^c,x   Stary, Jan ^y   Stasevich, Irina ^t   Strehl, Sabine ^j   Taga, Takashi ^v,z   Tomizawa, Daisuke ^v,aa   Webb, David ^q,ab   Zemanova, Zuzana ^ac   Pieters, Rob ^a   Zwaan, C Michel ^a,p   Van Den Heuvel Eibrink, Marry M ^a,p   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g Dutch Working Group on Hemato Oncologic Genome Diagnostics   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^k UMEÅ UNIVERSITY   (Sweden)

^l ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o OHIO STATE UNIVERSITY   (United States)

^p DCOG Dutch Childhood Oncology Group   (Netherlands)

^q Acute Myeloid Leukemia Committee I Berlin Frankfurt Münster Study Group   (Germany)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^s UNIVERSITY OF PADOVA   (Italy)

^t Belarusian Research Center for Pediatric Oncology and Hematology   (Belarus)

^u UNIVERSITY OF CATANIA   (Italy)

^v Japanese Pediatric Leukemia/Lymphoma Study Group   (Japan)

^w JICHI MEDICAL UNIVERSITY   (Japan)

^x UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^y UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^z SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^aa TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^ab GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^ac CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADDITIONAL CYTOGENETIC ABERRATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; EVENT FREE SURVIVAL; FEMALE; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TRISOMY; TRISOMY 19; TRISOMY 8;

EID: 79959822135     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-328302     Document Type: Article

References (45)

1. Balgobind BV, Zwaan CM, Reinhardt D, et al. High BRE expression in pediatric MLLrearranged AML is associated with favorable outcome. Leukemia. 2010;24(12):2048-2055.
2. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-2681.
3. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113(23):5951-5960.
4. Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):262-270.
5. Kuipers JE, Coenen EA, Balgobind BV, et al. High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Blood. 2011;117(3):928-935.
6. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-2689.
7. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
8. Balgobind BV, Zwaan CM, Meyer C, et al. NRIP3: a novel translocation partner of MLL detected in a pediatric acute myeloid leukemia with complex chromosome 11 rearrangements. Haematologica. 2009;94(7):1033.
9. Coenen EA, Zwaan CM, Meyer C, et al. KIAA1524: Anovel MLL translocation partner in acute myeloid leukemia. Leuk Res. 2011;35(1):133-135.
10. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/ MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
11. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
12. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499-4506. (Pubitemid 46646248)
13. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030-2042. (Pubitemid 41741595)
14. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. (Pubitemid 41741605)
15. Katano N, Tsurusawa M, Hirota T, et al. Treatment outcome and prognostic factors in childhood acute myeloblastic leukemia: a report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG). Int J Hematol. 1997;66(1):103-110. (Pubitemid 27297033)
16. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111(3):1044-1053. (Pubitemid 351213382)
17. Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol. 2003;122(2):217-225. (Pubitemid 36859606)
18. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082-2089. (Pubitemid 41741600)
19. Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19(12):2043-2053. (Pubitemid 41741596)
20. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005;19(12):2101-2116.
21. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH, Rubnitz JE. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia. 2005;19(12):2125- 2129.
22. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054-2062. (Pubitemid 41741597)
23. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2005.
24. Betts DR, Ammann RA, Hirt A, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007;78(6):468-476. (Pubitemid 46753600)
25. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112(1):118-126. (Pubitemid 32151159)
26. Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;22(16):3432-3433. (Pubitemid 41103704)
27. Balgobind BV, Hollink IH, Reinhardt D, et al. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Eur J Cancer. 2010;46(10):1892-1899.
28. Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942-949.
29. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica. 2011;96(2):221-230.
30. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, et al. Leukemiaassociated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111(8):4322-4328.
31. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol. 2010;28(28):e523-526; author reply e527-e528.
32. Hollink IH, van den Heuvel-Eibrink MM, Zwaan CM. CEBPAresembles Roman god Janus. Blood. 2009;113(26):6501-6502.
33. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94(11):3707-3716.
34. National Cancer Institute. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2010. http://cgap.nci.nih.gov/Chromosomes/ Mitelman. Accessed November 4, 2010.
35. Slater RM, von Drunen E, Kroes WG, et al. t(7; 12)(q36;p13) and t(7;12)(q32;p13) - translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia. 2001;15(6):915-920.
36. Länger F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res. 2005;29(3):325-329. (Pubitemid 40127060)
37. Alvarez S, Suela J, Valencia A, et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE. 2010;5(8):e12197.
38. Kok CH, Brown AL, Ekert PG, D'Andrea RJ. Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML. Leukemia. 2010;24(6):1239-1243.
39. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100(13):4427-4432. (Pubitemid 35429681)
40. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109(6):2399-2405. (Pubitemid 46425880)
41. Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia. 2005;19(12):2072-2081.
42. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
43. Göhring G, Michalova K, Beverloo HB, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116(19):3766-3769.
44. Stark B, Jeison M, Gabay LG, et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. Br J Haematol. 2004;126(3):320-337. (Pubitemid 39005712)
45. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.